EFFECTIVENESS OF SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS IN REDUCING HEART FAILURE HOSPITALIZATIONS IN DIABETIC PATIENTS

Abstract

The complication known as Heart Failure frequently affects type 2 diabetes mellitus patients while it raises their disease-related risks and medical expenses and mortality rates. The initial purpose of sodium-glucose cotransporter-2 (SGLT2) inhibitors to control diabetes mellitus resulted in new cardiovascular benefit discoveries which demonstrated effectiveness in preventing hospitalizations for heart failure (HHF). This review analyzes recent randomized controlled trial (RCT) evidence and meta-analysis findings as well as actual patient treatment data to determine SGLT2 inhibitor efficacy for heart failure hospitalization prevention in diabetes patients. Major heart failure reduction is possible through SGLT2 inhibitor treatment as shown by DAPA-HF and EMPEROR-Reduced trial results in both diabetic and non-diabetic patients. Meta-analytic results demonstrate that this treatment benefit reaches all patient groups in their investigations. SGLT2 inhibitors provide mechanisms beyond glucose management that lead to sodium loss through natriuretic effects while decreasing patient workload and improving heart tissue function and decreasing swelling. Research data proves the necessity of SGLT2 inhibitors in standard T2DM patient care particularly for patients who already have HF or who are at HF risk. The review points out the importance of beginning treatment right away and tailoring treatment approaches but also takes into account the diverse characteristics of patients together with varying research patterns. Analysis concludes that SGLT2 inhibitors perform effectively to decrease HHF events and they represent substantial revolutionary options within diabetic heart treatment.